HRQOL improvements in anemic CKD patients treated with darbepoetin alfa (Aranesp™)

被引：0
|
作者：
Ruhman, SN
Heifner, KJ
Fadem, SZ
Melvor, ME
Brenner, RM
Powers, KM
Ford, JM
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] St Petersburg Heart Ctr, St Petersburg, FL USA
[3] Huston Kidney Ctr, Houston, TX USA
[4] Renal Associates, Little Rock, AR USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2002年 / 39卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
66
引用
收藏
页码：A27 / A27
页数：1
相关论文
共 50 条
  • [21] Quality of life improvements in dialysis patients receiving darbepoetin alfa
    Fukuhara, Shunichi
    Akizawa, Tadao
    Morita, Satoshi
    Koshikawa, Shozo
    THERAPEUTIC APHERESIS AND DIALYSIS, 2008, 12 (01) : 72 - 77
  • [22] Aranesp®(Darbepoetin Alfa) in the management of anaemia in dialysis patients receiving high dose erythropoietin (rHuEPO).
    Jenkins, KJ
    John, RI
    Stevens, PE
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 498A - 498A
  • [23] Prediction of treatment response in anemic patients with cancer using darbepoetin alfa (DARB)
    Camara, O.
    Hartmann, M.
    Egbe, A.
    Koch, I.
    Runnebaum, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] HEMATOPOIETIC RESPONSE IN ANEMIC LUNG CANCER PATIENTS RECEIVING WEEKLY DARBEPOETIN ALFA
    Migliorino, Maria Rita
    De Petris, Luigi
    Martelli, Olga
    Mancuso, Andrea
    Di Salvia, Roberto
    De Marinis, Filippo
    ANNALS OF ONCOLOGY, 2004, 15 : 118 - 118
  • [25] A COMPARISON OF IV EPOETIN-ALFA (EPREX) AND DARBEPOETIN-ALFA (ARANESP) IN HAEMODIALYSIS PATIENTS IN THE PILBARA DIALYSIS UNIT
    Irish, A.
    Cochrane, R.
    NEPHROLOGY, 2007, 12 : A20 - A20
  • [26] Regarding "randomized comparison of epoetin alfa and darbepoetin alfa in anemic patients with cancer receiving chemotherapy" - In Reply
    Waltzman, Roger
    ONCOLOGIST, 2006, 11 (05): : 536 - 537
  • [27] Aranesp™ (darbepoetin alfa) administered once every other week (Q2W) corrects anemia in patients with chronic kidney disease (CKD)
    Lindberg, JS
    Navarro, J
    Suranyi, M
    Walker, R
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (04) : A22 - A22
  • [28] HEMATOLOGIC OUTCOMES AND DOSING PATTERNS IN ANEMIC PATIENTS WITH PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) SWITCHING FROM DARBEPOETIN ALFA (DARB) TO EPOETIN ALFA (EPO)
    Hura, Claudia
    Jackson, James
    Lunacsek, Orsolya
    Bailey, Robert A.
    McKenzie, R. Scott
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) : A65 - A65
  • [29] Neuroprotective effect of aranesp (Darbepoetin alfa) after cortical impact injury in rats
    Cherian, L
    Robertson, CS
    JOURNAL OF NEUROTRAUMA, 2006, 23 (05) : 793 - 793
  • [30] Use and outcomes of epoetin alfa and darbepoetin alfa for anemic cancer patients in outpatient community practice settings.
    Fahrbach, KR
    Frame, D
    Sercus, B
    Schenkel, B
    BLOOD, 2005, 106 (11) : 485B - 486B
12345